Qingsong Capital is an entrepreneurial private equity investment institution focusing on the investments in the field of biotechnology and medical health.
Meichuang Medical is an innovative medical device company that focuses on the R&D, manufacturing and commercialization of high-end medical devices in the fields of peripheral vascular intervention, tumor intervention, and hemodialysis access maintenance
Oukejian
Series A in 2025
Oukejian specializes in researching and developing innovative large-molecule drugs for prevalent fundus diseases.
Yili Pharmaceutical
Seed Round in 2024
Yili Pharmaceutical is a pharmaceutical R&D company that mainly engages in biochemical product technology R&D, medical research and experimental development, engineering and technology research and experimental development, and software development.
Worg Pharmaceuticals
Venture Round in 2024
Worg Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for allergies and other diseases with significant unmet medical needs. The company is constructing a robust pipeline targeting allergy and autoimmune disorders through two technology platforms, PCFiT and Apitope, leveraging both internal development and strategic collaborations. Additionally, Worg is advancing a platform for molecular allergy diagnosis, enhancing its capabilities in addressing allergy-related health issues. Through its flexible business models, Worg Pharmaceuticals aims to accelerate the development of effective immunotherapies and contribute to improved patient outcomes in the field of allergy and autoimmune diseases.
Weixu Biotechnology
Series A in 2024
Weixu Biotechnology is a livestock biotechnology business that produces and markets animal serum, animal blood products, and biological raw materials. It also offers sales and technical services for animal products, feed additives, microbiological preparations, animal nutritional health products, and feed raw materials.
Meson Technology
Angel Round in 2023
Meson Technology is a provider of chemical technology services specializing in the deployment of continuous-flow chemical technology systems. Its operations include continuous manufacturing methods for fine chemicals and biopharmaceutical goods, as well as continuous environmental protection treatment.
Cornerstone Robotics
Series B in 2023
Cornerstone Robotics is dedicated to enhancing the accessibility of advanced medical services in China through the development of medical robotic devices. The company is focused on creating a safe and efficient surgical robotics platform aimed at improving the accuracy and efficiency of surgical operations. By prioritizing research and development, Cornerstone Robotics enables physicians to perform surgeries with greater precision, ultimately contributing to better patient outcomes in the healthcare sector.
Suzhou Meichuang
Series A in 2023
Meichuang Medical is an innovative medical device company that focuses on the R&D, manufacturing and commercialization of high-end medical devices in the fields of peripheral vascular intervention, tumor intervention, and hemodialysis access maintenance
Bio-Engine
Series C in 2023
Bio-Engine specializes in the research and development of veterinary biological products, focusing on the creation and manufacturing of antibodies, recombinant proteins, and vaccines for both human and livestock viruses. The company utilizes high-density serum-free suspension culture technology for animal cells, which enhances the efficiency of its products. Key offerings include serum-free media for various cell types, such as HEK293 and PK15, applicable in fields like cell therapy and vaccine production. In addition to product development, Bio-Engine provides clinical trial services to pharmaceutical manufacturers and scientific research organizations. Founded in 2014 and headquartered in Shanghai, China, the company is committed to advancing biotechnological solutions in the veterinary sector.
Ouli Biomedical
Seed Round in 2023
Ouli Biomedical is a pharmaceutical company. They offer nucleic acid drug discovery, laboratory research and development, process and analysis development, CMC services, API production, and drug registration.
Cospowers
Series E in 2022
Cospowers is a technology-driven company that specializes in developing and manufacturing smart lithium battery solutions for a global clientele. Established in 2003, the company focuses on providing a one-stop comprehensive energy storage solution, which includes rechargeable batteries, chargers, and power battery packs. Cospowers employs advanced technology and scientific management methods to ensure product safety and reliability. Their offerings cater to various applications, including network energy, electric energy storage, and consumer batteries, promoting clean and efficient energy solutions. The products are well-received by customers, reflecting the company's commitment to quality and innovation in the energy storage sector.
CATUG Biotechnology
Venture Round in 2022
CATUG Biotechnology specializes in the development and application of advanced biomedical technologies, particularly in the fields of gene therapy and nucleic acid drugs. The company offers comprehensive contract development and manufacturing organization (CDMO) services, addressing the entire industry chain from research and development to clinical applications and industrialization. CATUG operates R&D centers and industrialization bases located in Suzhou and Wuhan, facilitating its focus on drug research and production services.
Ionova Life Science
Venture Round in 2021
Ionova Life Science Co., Ltd. is a biotechnology company based in Shenzhen, China, with additional offices in Hong Kong, Macao, and the Greater Bay Area. Founded in 2016, the company focuses on the discovery and development of novel medicines for cancer treatment, specializing in oncology, immuno-oncology, and tumor-targeted therapies. Ionova employs an in-house built discovery platform to facilitate the development of innovative anti-tumor drugs and immunomodulatory agents. Through its research efforts, the company aims to advance treatments that specifically target tumors and enhance the immune response against cancer.
Stemirna
Venture Round in 2021
Stemirna Therapeutics is a RNA technology based drug development company designed to maximize the potential of RNA science. The company currently has more than a dozen of independently-developed mRNA drug projects, focusing on the fields of mRNA-based personalized cancer vaccines, mRNA vaccines for infectious disease, protein defects diseases, and genetic diseases, providing cure and solutions for cancer and infectious diseases, better serving patients.
LaNova Medicines
Series A in 2021
LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.
MEDx
Series B in 2020
MEDx is a company specializing in precision medicine solutions aimed at enhancing clinical development. Founded in 2013 and headquartered in Suzhou, Jiangsu, MEDx employs translational science to advance diagnostic technologies related to nucleic acids and proteins. Its comprehensive services include biomarker development, Companion Diagnostics, Point-of-Care development, clinical testing, and the commercialization of medical products. By focusing on individualized treatment, MEDx seeks to improve patient outcomes through its innovative approaches in the healthcare sector.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.